Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025

Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the past few days the pharma giant has closed a multibillion‑dollar obesity acquisition, secured a major new U.S. cancer approval, sold $6 billion in new bonds and agreed to a $41.5 million legal settlement in Texas – while new analysis published today highlights both its long‑term potential and its risks. ^[1]

Below is a roundup of the latest news and analysis as of Sunday, November 23, 2025, with a focus on items dated today.

Pfizer stock snapshot: price, performance and dividend

Pfizer stock last closed on Friday, November 21, 2025 at about $25.04 per share, putting the company’s market capitalisation in the low‑$140 billion range and leaving shares more than 60% below their pandemic‑era peak above $50. ^[2] Over the past year, total shareholder return is modestly positive (around +4–5%), but year‑to‑date performance in 2025 remains slightly negative, underperforming the broader market. ^[3]

At this price, Pfizer trades on a price‑to‑earnings (P/E) multiple around the mid‑teens and a price‑to‑book (P/B) ratio near 1.5, a discount to many large pharmaceutical peers. Independent valuation work from Simply Wall St pegs fair value” around $29 per share, implying roughly 14% upside from current levels, though with notable execution and regulatory risk. ^[4]

The bigger headline for income investors is the near‑7% dividend yield. Pfizer’s board declared a $0.43 per‑share fourth‑quarter 2025 dividend, payable on December 1, 2025, marking the company’s 348th consecutive quarterly payout. At current prices this works out to a forward yield of roughly 6.8–6.9%, one of the highest among Big Pharma, and the company has increased its dividend for 16 consecutive years. ^[5]

Today’s new commentary: Pfizer picked as a long‑term healthcare play

DailyForex: Pfizer highlighted among best healthcare stocks to buy” (23 Nov)

In a piece published today, DailyForex includes Pfizer on a shortlist of healthcare stocks it sees as attractive defensive plays. The article emphasises: ^[6]

Valuation: Pfizer’s P/E ratio (about 14–15) sits far below the S&P 500’s ~29x, while its P/B of ~1.5 and price‑to‑sales below 3 mark it as value” relative to the broader market.
Profitability: Net margin around 15–16% and a positive spread between return on invested capital (ROIC) and weighted average cost of capital (WACC) suggest value creation rather than destruction. ^[7]
Income appeal: A dividend yield a little above 7% (using slightly lower price assumptions) is highlighted as compensation for regulatory and political risk in healthcare. ^[8]

Technically, DailyForex notes that PFE is trading in a support zone in the mid‑$20s, with upside potential if it can hold above recent lows. The author discloses a long position in Pfizer, underscoring the article’s bullish tilt. ^[9]

AInvest: Pfizer vs Viking Therapeutics as a 10‑year duo (23 Nov)

Also today, AInvest published a feature titled Balancing Risk and Reward: 2 High‑Potential Healthcare Stocks for 10‑Year Investors” that pairs Pfizer with Viking Therapeutics as a way to capture both defensive cash flow and GLP‑1 obesity growth. ^[10]

Key Pfizer points from that piece:

R&D vs cost cuts: Pfizer expects $10.7–$11.7 billion in R&D spend in 2025, underlining its push to refill the pipeline, while management targets roughly $4.5 billion in net operating cost savings by 2025 after already delivering around $4.0 billion through 2024. ^[11]
IRA headwinds: The Inflation Reduction Act’s Part D redesign is projected to trim about $1 billion from Pfizer’s 2025 revenue, a reminder that U.S. drug‑pricing reform remains an overhang for large pharma. ^[12]
Thesis: AInvest frames Pfizer as a strategic resilience” play – an established giant using cost discipline and heavy R&D to offset patent expirations and pricing pressure, including in obesity and cardiometabolic disease.

The article positions long‑term Pfizer holders as trading some near‑term growth for balance‑sheet strength, scale and diversification.

Institutional money moves in Pfizer: who’s buying and selling?

Several MarketBeat reports dated November 23, 2025 shine a light on how institutional investors have been repositioning around PFE: ^[13]

Prudential Financial Inc. increased its stake in Pfizer by 21.3% in Q2, buying roughly 1.27 million additional shares and bringing its total to about 7.24 million shares, or 0.13% of the company, valued around $175.5 million at the time of filing. ^[14]
Patrick Mauro Investment Advisor Inc. lifted its holdings by 17.9%, to approximately 457,000 shares, reinforcing interest from smaller institutional managers. ^[15]
Nemes Rush Group LLC, by contrast, cut its stake by 75.1%, selling 86,066 shares and leaving it with just 28,544 shares worth about $692,000. ^[16]

MarketBeat notes that around 68% of Pfizer’s shares are held by hedge funds and other institutions, with Wall Street’s consensus rating remaining Hold” and an average 12‑month price target near $28–$29, implying mid‑teens upside from Friday’s close. ^[17]

These filings don’t tell you what institutions are doing right now, but they show that large investors are still actively trading Pfizer – some leaning into the value and income story, others rotating out after recent news.

Recent catalysts behind the PFE story

While today’s commentary is fresh, it’s reacting to a series of major company events over the past few weeks.

1. Q3 2025 earnings: profit beat, COVID drag, guidance raised

On November 4, Pfizer reported third‑quarter 2025 revenue of $16.7 billion, down about 6–7% year‑on‑year, as COVID‑related products continued to decline. Adjusted diluted EPS came in at $0.87, beating expectations and marking one of the largest positive EPS surprises in healthcare this quarter. ^[18]

Key takeaways from the quarter:

Non‑COVID portfolio grew 4% operationally, with strength in brands like Eliquis, Nurtec and the Vyndaqel family partially offsetting vaccine weakness. ^[19]
COVID products suffered steep declines: Comirnaty vaccine revenue fell about 19% globally, while Paxlovid sales dropped 55%, reflecting softer demand and tougher year‑over‑year comparisons. ^[20]
Pfizer reaffirmed full‑year 2025 revenue guidance of $61–64 billion and raised its adjusted EPS guidance to $3.00–$3.15 from a prior range of $2.90–$3.10. ^[21]

Management emphasised progress on cost‑cutting, targeting roughly $7.7 billion in overall savings, including about $4.5 billion in net cost savings from its cost‑realignment programme. ^[22]

2. Metsera: a $10 billion bet on obesity drugs

On November 13, Pfizer completed its acquisition of Metsera, a clinical‑stage obesity biotech it had fought over in a high‑profile bidding war with Novo Nordisk. ^[23]

Deal structure and strategic significance:

Pfizer is paying up to $86.25 per share for Metsera, including $65.60 in cash and up to $20.65 in contingent value rights (CVRs) tied to pipeline milestones, valuing the deal at around $10 billion. ^[24]
Metsera’s pipeline features GLP‑1‑based obesity candidates, including once‑monthly injectable and oral therapies that have shown double‑digit percentage weight loss in mid‑stage trials, positioning Pfizer to re‑enter the booming obesity market it previously exited over safety concerns. ^[25]
Pfizer’s CFO has signalled plans to use Metsera to build a global obesity franchise and hinted at further dealmaking of up to roughly $5 billion to support this strategy. ^[26]

Today’s AInvest article leans heavily on Metsera as a key reason Pfizer can grow beyond its COVID windfall and looming patent cliff, while still funding its generous dividend. ^[27]

3. Oncology momentum: new bladder cancer approval

On November 21, the U.S. FDA approved PADCEV® (enfortumab vedotin) plus Keytruda® (pembrolizumab) as a perioperative (pre‑ and post‑surgery) treatment for adults with muscle‑invasive bladder cancer (MIBC) who cannot receive cisplatin‑based chemotherapy. ^[28]

According to Pfizer and partner Astellas:

The EV‑303 / KEYNOTE‑905 Phase 3 trial showed the combo cut the risk of disease recurrence, progression or death by 60% and reduced the risk of death by 50% versus surgery alone. ^[29]
PADCEV + Keytruda is now the first and only FDA‑approved perioperative regimen for these cisplatin‑ineligible MIBC patients, potentially setting a new standard of care and expanding Pfizer’s oncology revenue base. ^[30]

A Simply Wall St note published today argues that this approval strengthens Pfizer’s growth outlook and suggests shares remain about 14% undervalued despite a modest 12‑month share price recovery. ^[31]

4. Vaccines: mRNA flu win vs broader vaccine slump

Two headlines show the cross‑currents in Pfizer’s vaccine franchise:

A Phase 3 trial of Pfizer’s modRNA flu vaccine – now published in the New England Journal of Medicine – found that the shot outperformed a standard quadrivalent inactivated flu vaccine on immune responses to key A/H3N2 and A/H1N1 strains, though with more post‑shot side‑effects. Shares jumped almost 4% on November 21 as investors welcomed the data. ^[32]
Yet Q3 results show a broad vaccine slowdown: Prevnar pneumococcal vaccines, RSV shot Abrysvo and COVID vaccine Comirnaty all saw year‑on‑year sales declines, especially in the U.S., where vaccination uptake has softened. ^[33]

Investors today are weighing whether new platforms like mRNA flu can offset these declines over time.

Balance sheet moves: $6 billion bond sale and a long dividend streak

To support its pipeline and acquisitions, Pfizer has also been active in the bond market.

On November 21, the company completed a $6 billion public offering of senior notes across multiple maturities: ^[34]

$500 million floating‑rate notes due 2027
$1.0 billion 3.875% notes due 2027
$1.0 billion 4.200% notes due 2030
$1.25 billion 4.500% notes due 2032
$1.25 billion 4.875% notes due 2035
$500 million 5.600% notes due 2055
$500 million 5.700% notes due 2065

Investing.com notes that Pfizer has maintained dividend payments for 55 consecutive years and currently offers around a 6.9% yield, underlining management’s commitment to returning cash even while it raises capital for deals like Metsera. ^[35]

Legal and political backdrop: Texas settlement and tariff deal

Texas ADHD settlement

On November 19, Pfizer and supplier Tris Pharma agreed to pay $41.5 million to settle a Texas lawsuit alleging they misrepresented the quality of Quillivant XR, a liquid ADHD drug for children, to keep it eligible for Medicaid reimbursement. ^[36]

Texas prosecutors alleged manipulated quality‑control tests between 2012 and 2018, claiming some batches failed to dissolve properly and were therefore ineffective.
Pfizer denied wrongdoing and said its review did not find any impact on patient safety; Tris did not comment publicly in the Reuters report. ^[37]

The settlement removes an overhang but underscores ongoing legal and reputational risks around drug quality and marketing.

Trump‑era tariffs and drug‑pricing deals

Pfizer also remains in the spotlight in U.S. drug‑pricing politics. Earlier this autumn, the company negotiated a deal with the Trump administration that allowed it to avoid tariffs on its drugs by agreeing to lower some prices and increase U.S. manufacturing. ^[38]

Analyst coverage following that arrangement – including an Outperform rating reaffirmed at BMO – has framed the company as relatively well insulated from the harshest potential trade measures, albeit at the cost of some pricing power. ^[39]

These policy compromises, combined with IRA‑related headwinds, are central to today’s valuation debates around PFE.

How Wall Street sees Pfizer now

A detailed November 5 analysis from TechStock² captures the split sentiment around the stock: TechStock²+1

Share price collapse: PFE has lost more than 60% of its value from its COVID‑vaccine peak and remains down roughly 8–10% in 2025 despite a recent bounce.
Income appeal: The dividend yield sits near 7%, far above market averages, and the payout has grown annually for 16 years – though some commentators worry a very large acquisition spree could eventually pressure the dividend. TechStock²+2Dividend.com+2
Analyst stance: Of roughly 18 analysts tracked, about two‑thirds rate Pfizer a Hold”, with a minority on Buy” or Strong Buy” and only one Sell”, and an average price target around $28–$29 per share. TechStock²+1

Other recent research – including a Nasdaq piece asking whether Pfizer’s 6.9% yield is still safe” – generally concludes that the dividend is covered under current guidance, but warns that execution on obesity, oncology and cost savings will be crucial to sustain both the payout and any re‑rating. ^[40]

Key risks and watchpoints after today

Pulling together today’s new analysis with recent news, investors and observers will likely focus on several questions heading into year‑end:

Can Metsera deliver?
The Metsera deal is a $10 billion bet that Pfizer can carve out meaningful share in the GLP‑1 obesity market currently dominated by Novo Nordisk and Eli Lilly. Any new clinical data, regulatory updates or guidance on launch timing will be closely watched. ^[41]
Will oncology offset vaccine softness?
The PADCEV + Keytruda approval for MIBC is a major win, but the magnitude of its commercial impact will depend on uptake in a specialised population and competition in bladder cancer. ^[42]
Dividend sustainability vs leverage
A high dividend plus additional debt for acquisitions and bond offerings raises the stakes on cash‑flow execution. Investors will monitor free‑cash‑flow trends, future bond issues and any hints of dividend policy changes. ^[43]
Regulation and litigation
From the Texas ADHD settlement to IRA pricing rules and Trump‑era tariff deals, Pfizer faces a complex regulatory environment that can swing sentiment quickly. Any new lawsuits, government pricing actions or investigations could introduce volatility. ^[44]
Execution on cost savings
Much of Pfizer’s raised EPS guidance depends on hitting aggressive cost‑cutting targets rather than top‑line growth. Investors will look for evidence in 2026 guidance that margin gains are sustainable without undermining R&D productivity. ^[45]

Pfizer enters the final weeks of 2025 as a classic show‑me” stock: cheap on earnings, rich in pipeline headlines, but still working through the hangover of its COVID windfall and looming patent expiries. Today’s fresh commentary from DailyForex, AInvest and MarketBeat underscores the split view – some see a high‑yield value opportunity anchored by Metsera and oncology wins; others worry the company is using cost cuts and financial engineering to paper over a tougher growth reality.

For readers and investors following PFE, the next major signposts will likely be 2026 guidance, early obesity‑drug updates from Metsera’s pipeline, and real‑world uptake of its new cancer and vaccine launches.

Pfizer Revolutionizes Cancer and COVID Treatments $PFE #stonks #investing #genbet